Zacks Research Analysts Increase Earnings Estimates for ALLO

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Analysts at Zacks Research raised their Q1 2025 earnings per share (EPS) estimates for Allogene Therapeutics in a report issued on Wednesday, April 2nd. Zacks Research analyst R. Department now expects that the company will post earnings of ($0.31) per share for the quarter, up from their previous estimate of ($0.37). The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.28) per share. Zacks Research also issued estimates for Allogene Therapeutics’ Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.26) EPS, Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.40) EPS.

Other equities analysts also recently issued reports about the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $14.00 price target on shares of Allogene Therapeutics in a research note on Friday, March 14th. HC Wainwright dropped their target price on Allogene Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, March 19th. Citizens Jmp upgraded Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a report on Friday, March 14th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a report on Friday, March 14th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Allogene Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.29.

Allogene Therapeutics Stock Performance

Allogene Therapeutics stock opened at $1.44 on Monday. The firm’s 50 day moving average price is $1.81 and its two-hundred day moving average price is $2.19. The firm has a market cap of $312.86 million, a PE ratio of -0.92 and a beta of 0.99. Allogene Therapeutics has a twelve month low of $1.30 and a twelve month high of $4.25.

Allogene Therapeutics (NASDAQ:ALLO) last released its earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.06.

Insider Activity at Allogene Therapeutics

In other news, CEO David D. Chang sold 46,668 shares of Allogene Therapeutics stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $1.96, for a total value of $91,469.28. Following the transaction, the chief executive officer now owns 5,276,569 shares of the company’s stock, valued at $10,342,075.24. This trade represents a 0.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Zachary Roberts sold 27,199 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total transaction of $48,414.22. Following the completion of the sale, the executive vice president now owns 488,054 shares of the company’s stock, valued at $868,736.12. The trade was a 5.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 104,866 shares of company stock valued at $194,461. Corporate insiders own 24.30% of the company’s stock.

Institutional Investors Weigh In On Allogene Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. abrdn plc acquired a new position in shares of Allogene Therapeutics during the 4th quarter worth about $776,000. Barclays PLC increased its position in Allogene Therapeutics by 101.5% in the 3rd quarter. Barclays PLC now owns 342,973 shares of the company’s stock worth $959,000 after buying an additional 172,745 shares during the period. Zacks Investment Management acquired a new position in shares of Allogene Therapeutics during the third quarter worth approximately $1,446,000. Geode Capital Management LLC boosted its position in shares of Allogene Therapeutics by 14.4% in the third quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock valued at $9,037,000 after acquiring an additional 407,070 shares during the period. Finally, Vontobel Holding Ltd. grew its stake in shares of Allogene Therapeutics by 788.4% in the fourth quarter. Vontobel Holding Ltd. now owns 195,457 shares of the company’s stock worth $416,000 after acquiring an additional 173,457 shares during the last quarter. 83.63% of the stock is owned by institutional investors and hedge funds.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).